Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EMIS NASDAQ:FLXN NYSE:KDMN NASDAQ:TXMD OTCMKTS:VEGPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$25.61+0.3%$9.20$4.30▼$13.66$1.29B1.531.18 million shs772 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsTXMDTherapeuticsMD$1.25+19.6%$1.09$0.70▼$2.44$14.47M0.5818,040 shs8.72 million shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics-0.39%-0.02%-0.31%+1.90%+179.93%KDMNKadmon0.00%0.00%0.00%0.00%0.00%TXMDTherapeuticsMD+19.62%+20.19%+17.92%+8.70%-20.89%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$25.61+0.3%$9.20$4.30▼$13.66$1.29B1.531.18 million shs772 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsTXMDTherapeuticsMD$1.25+19.6%$1.09$0.70▼$2.44$14.47M0.5818,040 shs8.72 million shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics-0.39%-0.02%-0.31%+1.90%+179.93%KDMNKadmon0.00%0.00%0.00%0.00%0.00%TXMDTherapeuticsMD+19.62%+20.19%+17.92%+8.70%-20.89%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMISEmisphere Technologies 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/AKDMNKadmon 0.00N/AN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/AVEGPFVectura Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TXMD, VEGPF, EMIS, FLXN, and KDMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025TXMDTherapeuticsMDWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TXMDTherapeuticsMDWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics$85.55M15.07N/AN/A($0.34) per share-75.34KDMNKadmonN/AN/AN/AN/AN/AN/ATXMDTherapeuticsMD$1.76M8.22N/AN/A$2.37 per share0.53VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/ATXMDTherapeuticsMD-$2.18MN/A0.00∞N/A-17.94%-2.01%-1.40%11/11/2025 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ALatest TXMD, VEGPF, EMIS, FLXN, and KDMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025TXMDTherapeuticsMDN/A$0.05N/A$0.05N/A$0.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMISEmisphere TechnologiesN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05KDMNKadmonN/AN/AN/ATXMDTherapeuticsMDN/A2.892.89VEGPFVectura GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMISEmisphere TechnologiesN/AFLXNFlexion Therapeutics90.01%KDMNKadmonN/ATXMDTherapeuticsMD30.74%VEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipEMISEmisphere Technologies72.90%FLXNFlexion Therapeutics9.13%KDMNKadmonN/ATXMDTherapeuticsMD2.30%VEGPFVectura GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataKDMNKadmonN/A178.52 millionN/AOptionableTXMDTherapeuticsMD42011.57 million11.31 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableTXMD, VEGPF, EMIS, FLXN, and KDMN HeadlinesRecent News About These CompaniesPhilip Morris closes on the sale of Vectura GroupJanuary 2, 2025 | msn.comM&A News: Philip Morris (NYSE:PM) Will Sell Vectura for $198MSeptember 17, 2024 | msn.comVectura and Hikma to develop US asthma genericAugust 20, 2024 | pharmaphorum.comPEuropean Stocks See Mixed Session as U.K.'s FTSE LeadsJanuary 16, 2023 | thestreet.comVECTURA GROUP LS -,000271 (V4TA.BE)January 15, 2023 | finance.yahoo.comVectura Group PLC (V4TA.BE)January 9, 2023 | finance.yahoo.comResults for 'Vectura-Fertin Pharma'October 11, 2022 | afaqs.comAVectura Group (OTC:VEGPF), Short Interest ReportJuly 18, 2022 | benzinga.comCarlyle stays in race for VecturaAugust 27, 2021 | uk.finance.yahoo.comForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826August 27, 2021 | finance.yahoo.comPhilip Morris chief attacks critics as Vectura bid tests investorsAugust 20, 2021 | uk.finance.yahoo.comMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closerAugust 13, 2021 | uk.finance.yahoo.comVectura auction called off after Carlyle declines to beat Philip Morris bidAugust 10, 2021 | uk.finance.yahoo.comUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorAugust 9, 2021 | finance.yahoo.comPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringAugust 9, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTXMD, VEGPF, EMIS, FLXN, and KDMN Company DescriptionsEmisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Kadmon NYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.TherapeuticsMD NASDAQ:TXMD$1.25 +0.21 (+19.62%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.18 -0.07 (-5.60%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Vectura Group OTCMKTS:VEGPF$1.77 0.00 (0.00%) As of 11/1/2021Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
